Clinical perspective on aztreonam lysine for inhalation in patients with cystic fibrosis

References

• Cystic Fibrosis FoundationCystic Fibrosis Foundation Patient Registry 2008 annual data reportBethesda, MDCystic Fibrosis Foundation2009
   Google Scholar
• FlumePAO’SullivanBPRobinsonKACystic fibrosis pulmonary guidelines: Chronic medications for maintenance of lung healthAm J Respir Crit Care Med200717695796917761616
   PubMed Web of Science ®Google Scholar
• O’SullivanBPFreedmanSDCystic fibrosisLancet20093731891190419403164
   PubMed Web of Science ®Google Scholar
• MontgomeryGSHowenstineMCystic fibrosisPediatr Rev20093030230919648261
   PubMed Web of Science ®Google Scholar
• GibsonRLBurnsJLRamseyBWPathophysiology and management of pulmonary infections in cystic fibrosisAm J Respir Crit Care Med200316891895114555458
   PubMed Web of Science ®Google Scholar
• PamukcuABushABuchdahlREffects of Pseudomonas aeruginosa colonization on lung function and anthropometric variables in children with cystic fibrosisPediatr Pulmonol19951910157675552
   PubMed Web of Science ®Google Scholar
• HenryRLMellisCMPetrovicLMucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosisPediatr Pulmonol1992121581611641272
   PubMed Web of Science ®Google Scholar
• EmersonJRosenfeldMMcNamaraSRamseyBGibsonRLPseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosisPediatr Pulmonol2002349110012112774
   PubMed Web of Science ®Google Scholar
• KeremECoreyMGoldRLevisonHPulmonary function and clinical course in patients with cystic fibrosis after pulmonary colonization with Pseudomonas aeruginosaJ Pediatr19901167147192109790
   PubMed Web of Science ®Google Scholar
• FlumePARobinsonKAO’SullivanBPCystic fibrosis pulmonary guidelines: Airway clearance therapiesRespir Care20095452253719327189
   PubMed Web of Science ®Google Scholar
• FlumePAMogayzelPJJrRobinsonKACystic fibrosis pulmonary guidelines: Treatment of pulmonary exacerbationsAm J Respir Crit Care Med200918080280819729669
   PubMed Web of Science ®Google Scholar
• EmersonJMcNamaraSBuccatAMWorrellKBurnsJLChanges in cystic fibrosis sputum microbiology in the United States between 1995 and 2008Pediatr Pulmonol20104536337020232473
   PubMed Web of Science ®Google Scholar
• MendelmanPMSmithALLevyJWeberARamseyBDavisRLAminoglycoside penetration, inactivation, and efficacy in cystic fibrosis sputumAm Rev Respir Dis19851327617653931522
   PubMed Web of Science ®Google Scholar
• LevyJAntibiotic activity in sputumJ Pediatr19861088418463701536
   PubMed Web of Science ®Google Scholar
• TOBI (Package Insert)East Hanover, NJNovartis Pharmaceuticals Corporation2010
   Google Scholar
• RamphalRLhermitteMFilliatMRousselPThe binding of antipseudomonal antibiotics to macromolecules from cystic fibrosis sputumJ Antimicrob Chemother1988224834903060459
   PubMed Web of Science ®Google Scholar
• PotterJLMatthewsLWSpectorSLemmJComplex formation between basic antibiotics and deoxyribonucleic acid in human pulmonary secretionsPediatrics1965367147205844004
   PubMed Web of Science ®Google Scholar
• VaudauxPWaldvogelFAGentamicin inactivation in purulent exudates: Role of cell lysisJ Infect Dis19801425865937441018
   PubMed Web of Science ®Google Scholar
• GellerDEKonstanMWSmithJNoonbergSBConradCNovel tobramycin inhalation powder in cystic fibrosis subjects: Pharmacokinetics and safetyPediatr Pulmonol20074230731317352404
   PubMed Web of Science ®Google Scholar
• HagermanJKHancockKEKlepserMEAerosolised antibiotics: A critical appraisal of their useExpert Opin Drug Deliv20063718616370941
   PubMedGoogle Scholar
• GellerDEAerosol antibiotics in cystic fibrosisRespir Care20095465867019393109
   PubMed Web of Science ®Google Scholar
• MacLeodDLBarkerLMSutherlandJLAntibacterial activities of a fosfomycin/tobramycin combination: A novel inhaled antibiotic for bronchiectasisJ Antimicrob Chemother20096482983619679597
   PubMed Web of Science ®Google Scholar
• ConradDFlumePSindelLPhase 2b study of inhaled MP-376 (Aeroquin, levofloxacin inhalation solution) in stable cystic fibrosis (CF) patients with chronic Pseudomonas aeruginosa (PA) lung infectionAm J Respir Crit Care Med2010181A2339
   Google Scholar
• Cayston (Package Insert)Foster City, CAGilead Sciences, Inc2010
   Google Scholar
• Azactam (Package Insert)Princeton, NJBristol-Myers Squibb2010
   Google Scholar
• DietzschHJGottschalkBHeyneKLeupoidWWunderlichPCystic fibrosis: Comparison of two mucolytic drugs for inhalation treatment (acetylcysteine and arginine hydrochloride)Pediatrics197555961001110869
   PubMed Web of Science ®Google Scholar
• SapienzaMAKharitonovSAHorvathIChungKFBarnesPJEffect of inhaled L-arginine on exhaled nitric oxide in normal and asthmatic subjectsThorax1998531721759659350
   PubMed Web of Science ®Google Scholar
• ShawarRMMacLeodDLGarberRLActivities of tobramycin and six other antibiotics against Pseudomonas aeruginosa isolates from patients with cystic fibrosisAntimicrob Agents Chemother1999432877288010582875
   PubMed Web of Science ®Google Scholar
• BevivinoADalmastriCTabacchioniSBurkholderia cepacia complex bacteria from clinical and environmental sources in Italy: Genomovar status and distribution of traits related to virulence and transmissibilityJ Clin Microbiol20024084685111880403
   PubMed Web of Science ®Google Scholar
• BergGRoskotNSmallaKGenotypic and phenotypic relationships between clinical and environmental isolates of Stenotrophomonas maltophiliaJ Clin Microbiol1999373594360010523559
   PubMed Web of Science ®Google Scholar
• GibsonRLRetsch-BogartGZOermannCMicrobiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosisPediatr Pulmonol20064165666516703579
   PubMed Web of Science ®Google Scholar
• Retsch-BogartGZBurnsJLOttoKLA phase 2 study of aztreonam lysine for inhalation to treat patients with cystic fibrosis and Pseudomonas aeruginosa infectionPediatr Pulmonol200843475818041081
   PubMed Web of Science ®Google Scholar
• McCoyKSQuittnerALOermannCMGibsonRLRetsch-BogartGZMontgomeryABInhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosisAm J Respir Crit Care Med200817892192818658109
   PubMed Web of Science ®Google Scholar
• RamseyBWPepeMSQuanJMIntermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study GroupN Engl J Med199934023309878641
   PubMed Web of Science ®Google Scholar
• HagermanJKKnechtelSAKlepserMETobramycin solution for inhalation in cystic fibrosis patients: A review of the literatureExpert Opin Pharmacother2007846747517309341
   PubMed Web of Science ®Google Scholar
• Retsch-BogartGZQuittnerALGibsonRLEfficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosisChest20091351223123219420195
   PubMed Web of Science ®Google Scholar
• Aztreonam for inhalation solution (NDA 50–814) for improvement of respiratory symptoms in cystic fibrosis patients FDA briefing document for anti-infective drugs advisory committee meeting. December 10, 2009. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Anti-InfectiveDrugsAdvisoryCommittee/UCM193023.pdf. Accessed May 24, 2010.
   Google Scholar
• OermannCMRetsch-BogartGMcCoyKSGibsonRQuittnerALMontgomeryBEffect of multiple courses of aztreonam for inhalation solution (AZLI) on disease-related endpoints and safety in patients with CF: Final analysis of 18 month data [Abstr]Pediatr Pulmonol200944296
   Google Scholar
• OermannCMMcCoyKSRetsch-BogartGZGibsonRMcKevittMMontgomeryBEffect of repeated exposure to aztreonam for inhalation solution (AZLI) therapy on cystic fibrosis respiratory pathogens [Abstr]Pediatr Pulmonol200944335336
   Google Scholar
• OermannCMMcCoyKSRetsch-BogartGZGibsonRMcKevittMMontgomeryBAntibiotic susceptibility in Pseudomonas aeruginosa (PA) isolates following repeated exposures to aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis [Abstr]Pediatr Pulmonol20094430919283836
   PubMed Web of Science ®Google Scholar
• QuittnerALBuuAEffects of tobramycin solution for inhalation on global ratings of quality of life in patients with cystic fibrosis and Pseudomonas aeruginosa infectionPediatr Pulmonol20023326927611921456
   PubMed Web of Science ®Google Scholar
• Aztreonam for inhalation solution (AZLI) vs tobramycin inhalation solution (TOBI®) in patients with CF and P. aeruginosa. Available at: http://clinicaltrials.gov/ct2/show/NCT0757237. Accessed May 25, 2010.
   Google Scholar
• Specialty TrendsRx Alert. Cayston (aztreonam for inhalation solution) CVS Caremark, March 2010. Available at: https://www.caremark.com/portal/asset/SpecialtyTrendsRxAlert_Cayston.pdf. Accessed Jul 16, 2010.
   Google Scholar
• SRS Pharmacy Systems Available at: www.srspharmacy.com. Accessed Jul 16, 2010.
   Google Scholar